Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response

被引:88
作者
Gertz, Morie A. [1 ]
Lacy, Martha Q. [1 ]
Dispenzieri, Angela [1 ]
Hayman, Suzanne R. [1 ]
Kumar, Shaji K. [1 ]
Leung, Nelson [2 ]
Gastineau, Dennis A. [1 ]
机构
[1] Mayo Clin, Div Hematol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN 55905 USA
关键词
amyloidosis; chemotherapy; complete response; immunoglobulin free light chain; stem cell transplant; survival;
D O I
10.3324/haematol.11413
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our objective was to determine whether the goal of high-dose therapy should be a partial hematologic response or a complete response. We analyzed 282 consecutive stem cell transplant patients. A partial hematologic response was achieved in 108 patients (38%), and 93 (33%) achieved a complete hematologic response. Survival rates of patients with complete, partial, or no response were significantly different (p<0.001), even after eliminating bias from early death. The degree of response was affected by the intensity of chemotherapy conditioning, septal thickness, and cardiac biomarkers. Hematologic response translates to longer survival.
引用
收藏
页码:1415 / 1418
页数:4
相关论文
共 21 条
[1]  
BALDINI L, 1991, CANCER-AM CANCER SOC, V68, P62, DOI 10.1002/1097-0142(19910701)68:1<62::AID-CNCR2820680112>3.0.CO
[2]  
2-6
[3]   High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission.: Results of a non-randomized study from a single institution [J].
Bladé, J ;
Esteve, J ;
Rives, S ;
Martínez, C ;
Rovira, M ;
Urbano-Ispizua, A ;
Marín, P ;
Carreras, E ;
Montserrat, E .
BONE MARROW TRANSPLANTATION, 2000, 26 (08) :845-849
[4]   Serum free light chain measurements move to center stage [J].
Bradwell, AR .
CLINICAL CHEMISTRY, 2005, 51 (05) :805-807
[5]   Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation [J].
Dispenzieri, A ;
Lacy, MQ ;
Katzmann, JA ;
Rajkumar, SV ;
Abraham, RS ;
Hayman, SR ;
Kumar, SK ;
Clark, R ;
Kyle, RA ;
Litzow, MR ;
Inwards, DJ ;
Ansell, SM ;
Micallef, IM ;
Porrata, LF ;
Elliott, MA ;
Johnston, PB ;
Greipp, PR ;
Witzig, TE ;
Zeldenrust, SR ;
Russell, SJ ;
Gastineau, D ;
Gertz, MA .
BLOOD, 2006, 107 (08) :3378-3383
[6]   Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins [J].
Dispenzieri, A ;
Kyle, RA ;
Gertz, MA ;
Therneau, TM ;
Miller, WL ;
Chandrasekaran, K ;
McConnell, JP ;
Burritt, MF ;
Jaffe, AS .
LANCET, 2003, 361 (9371) :1787-1789
[7]   Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in southwest oncology group chemotherapy trials [J].
Durie, BGM ;
Jacobson, J ;
Barlogie, B ;
Crowley, J .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1857-1863
[8]   Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate [J].
Gertz, MA ;
Lacy, MQ ;
Dispenzieri, A ;
Ansell, SM ;
Elliott, MA ;
Gastineau, DA ;
Inwards, DJ ;
Micallef, INM ;
Porrata, LF ;
Tefferi, A ;
Litzow, MR .
BONE MARROW TRANSPLANTATION, 2004, 34 (12) :1025-1031
[9]   Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis [J].
Gertz, MA ;
Comenzo, R ;
Falk, RH ;
Fermand, JP ;
Hazenberg, BP ;
Hawkins, PN ;
Merlini, G ;
Moreau, P ;
Ronco, P ;
Sanchorawala, V ;
Sezer, O ;
Solomon, A ;
Grateau, G .
AMERICAN JOURNAL OF HEMATOLOGY, 2005, 79 (04) :319-328
[10]   Outcome of autologous stem cell transplantation for AL amyloidosis in the UK [J].
Goodman, Hugh J. B. ;
Gillmore, Julian D. ;
Lachmann, Helen J. ;
Wechalekar, Ashutosh D. ;
Bradwell, Arthur R. ;
Hawkins, Philip N. .
BRITISH JOURNAL OF HAEMATOLOGY, 2006, 134 (04) :417-425